Riskpilot← Back to searchSign inGet full accessHAEMOMEDTEC ApS
APSBankruptCVR 32358918Industrivej 24Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20094 employees
Revenue 2023
DKK 2,8M
+134% vs 2022
EBITDA margin
-11.6%
+57% vs 2022
Equity ratio
-178.9%
Financial strength
Net profit 2023
DKK -508K
+40% vs 2022
| Revenue | DKK 2,8M | +134% |
| EBITDA | DKK -323K | +57% |
| Net profit | DKK -508K | +40% |
| Total assets | DKK 4,2M | +75% |
| Equity | DKK -7,6M | -7% |
| Employees | 4 | — |
Legal name
HAEMOMEDTEC ApS
CVR number
32358918
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
4. juli 2009
Share capital
DKK 250.000
Employees
4 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren og bestyrelsesformanden i forening
Address
Industrivej 24
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -390 | -313 | 435 | 750 | 814 | 928 | 939 | 1.387 | 2.390 | 452 | 1.187 | 2.774 |
| Staff expenses | -1.310 | -1.671 | -802 | -782 | -824 | -797 | -769 | -769 | -911 | -2.198 | -1.943 | -3.097 |
| EBITDA | -1.699 | -1.985 | -367 | -31 | -11 | 130 | 170 | 618 | 1.478 | -1.746 | -756 | -323 |
| Depreciation & amort. | -110 | -110 | 260 | -7 | -4 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -1.809 | -2.095 | -627 | -39 | -15 | 130 | 170 | 618 | 1.478 | -1.746 | -756 | -323 |
| Net financials | -145 | -367 | -436 | -418 | -186 | -206 | -154 | -93 | -147 | -65 | -89 | -186 |
| Profit before tax | -1.955 | -2.462 | -1.064 | -457 | -201 | -76 | 16 | 525 | 1.331 | -1.811 | -845 | -508 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -1.955 | -2.462 | -1.064 | -457 | -201 | -76 | 16 | 525 | 1.331 | -1.811 | -845 | -508 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.136 | 1.456 | 1.474 | 1.985 | 1.520 | 1.728 | 2.365 | 1.788 | 5.280 | 3.943 | 2.422 | 4.242 |
| Equity | -2.036 | -4.497 | -5.561 | -6.018 | -6.219 | -6.295 | -6.278 | -5.753 | -4.422 | -6.233 | -7.078 | -7.587 |
| Long-term debt | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3.171 | 5.954 | 7.035 | 8.004 | 7.739 | 8.023 | 8.643 | 7.541 | 9.703 | 10.177 | 9.500 | 11.828 |
| Total debt | 3.171 | 5.954 | 7.035 | 8.004 | 7.739 | 8.023 | 8.643 | 7.541 | 9.703 | 10.177 | 9.500 | 11.828 |
EBITDA margin
-11.6%
This company
15.8%
Market median
-173% vs market
20122023
Equity ratio
-178.9%
This company
38.2%
Market median
-568% vs market
20122023
Return on equity
-50841800.0%
This company
18.4%
Market median
-276314230% vs market
20122023
Net profit margin
-18.3%
This company
8.1%
Market median
-326% vs market
20122023
Asset turnover
0.65×
This company
1.12×
Market median
-42% vs market
20122023
Debt / equity
1.56×
This company
0.62×
Market median
-152% vs market
20122023
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via CVR / Virk · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via CVR / Virk · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via CVR / Virk · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via CVR / Virk · Period 2015-07-01 – 2016-06-30
- Annual report 2015Filed via CVR / Virk · Period 2014-07-01 – 2015-06-30
- Annual report 2014Filed via CVR / Virk · Period 2013-07-01 – 2014-06-30
- Annual report 2013Filed via CVR / Virk · Period 2012-07-01 – 2013-06-30
- Annual report 2012Filed via CVR / Virk · Period 2011-07-01 – 2012-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BT Management | Management | 2011 | — | — |
LT Management | Management | 2009 | — | — |
SB Founder | Founder | 2009 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2010 | — | — | |
| Board of Directors | 2010 | — | — | |
| Chairman | 2009 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
KRATH HOLDING ApS | Company | 50.0% | 50.0% | 2009 |
BH HOLDING AF 22/12 2009 ApS | Company | 50.0% | 50.0% | 2009 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of HAEMOMEDTEC ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bue Thorn Svendsen | Management | 0 companies |
| Lasse Tybo Stougaard | Management | 0 companies |
| Systolé Beheer B.V. | Founder | 0 companies |
| Karl-Anker Krath | Chairman | 0 companies |
| Lis Krath | Board of Directors | 0 companies |
| Robert Johannes Den Engelsman | Chairman | 0 companies |